enzymology-and-biotechnology-congress-2017_posters

4 / 22

Page 82
Notes:
conferenceseries.com
Volume 7, Issue 1 (Suppl) J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal
March 20-21, 2017 Rome, Italy
&
15th World Congress on
2nd International Conference on
Biotechnology And Biotech Industries Meet
Enzymology and Molecular Biology
Enzymology & Mol. Biology 2017
Biotechnology Congress 2017
March 20-21, 2017
Construction, expression and characterization of a cancer-specific fusion protein targeting CD22 in B-cell
malignancies
Solmaz Agha Amiri1, 2, Najmeh Zarei2, Dorsa Khorasanizadeh2, Elahe Aminelahi2, Soraya Shahhosseini1 and Vahid Khalaj2
1Shahid Beheshti University of Medical Sciences, Iran
2Pasteur Institute of Iran, Iran
Dual-function proteins are a new class of therapeutics that composed of an antibody or antibody fragment linked to a cytotoxic
molecule to facilitate the targeted delivery and destruction of malignant cells. CD22 is a highly internalizing B-cell specific
surface antigen which overexpressed in 60%-80% of different types of B-cell malignancies. Therefore, anti-CD22 antibodies are ideal
candidates for targeted intracellular delivery of antitumor agents. Apoptin is a small 13KDa protein which can induce apoptosis in
tumor and transformed cells but not in normal cells. Hence, the apoptin protein can be used as a toxic moiety in development of
cancer -specific fusion proteins. In this study, we generated a novel dual function protein by fusing apoptin to the C-terminus of a
humanized anti CD-22 scFv; the anti-CD22 scFv portion of the protein targets the whole molecule to the tumors, while apoptin
executes specific killing functions. Using the routine molecular methods, the recombinant anti-CD22 scFv-apoptin protein was
expressed in E. coli and then purified. The in-vitro binding analyses by immunofluorescence and flow cytometry demonstrated that
the anti-CD22 scFv specifically bind to Raji CD22 positive cells and almost not to Jurkat CD22 negative cells. Evaluation of apoptotic
property of anti-CD22 scFv-apoptin using flow cytometry showed that following specific binding of anti-CD22 scFv-apoptin, the
protein induced apoptosis significantly in Raji cells (p<0.05). In conclusion, we have successfully produced functional anti-CD22
scFv-apoptin in E.coli. This recombinant protein may offer a new opportunity for the treatment of CD22+ B-cell malignancies.
Biography
Solmaz Agha Amiri is currently pursuing her PhD in the field of Pharmaceutical Biotechnology at Shahid Beheshti University of Iran. She has published five papers
in reputed journals.
Solmaz Agha Amiri et al., J Biotechnol Biomater 2017, 7:1(Suppl)